Halminen J, Sattaer N, Rawshani A et al (2022) Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes
How does my genetics affect weight rebound when I stop GLP-1
This article will review the role of GLP-1 in lipid metabolism in detail
A large 2026 analysis of more than 9,000 patients found that people who stopped semaglutide or tirzepatide regained an average of nearly 2 pounds a month
Barriers to insulin injection therapy: Patient and health care provider perspectives
States with no obesity GLP-1 coverage: Most remaining states including Texas, Florida, Ohio, New Jersey, and Georgia do not cover GLP-1s for obesity at all